Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 2 | — | — | — | 2 |
Drug common name | Eftilagimod alfa |
INN | eftilagimod alfa |
Description | Eftilagimod alfa is a fusion protein pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Fusion protein |
Drug class | Fc fusion protein; immunomodulators |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594557 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | SJ82PK3HWA (ChemIDplus, GSRS) |